TBPH Q2 2020 Earnings — Theravance Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

TBPHTheravance Biopharma, Inc.

$697M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$15M-42.6% YoY

Gross Profit

$15M100.0% margin

Operating Income

-$72M-480.9% margin

Net Income

-$63M-419.0% margin

EPS (Diluted)

$-1.00

QoQ Revenue Growth

-24.4%

Cash Flow

Operating Cash Flow

-$53M

Free Cash Flow

-$56M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$564M

Total Liabilities

$767M

Stockholders' Equity

-$202M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$15M	$26M	-42.6%
Gross Profit	$15M	-$20M	+174.1%
Operating Income	-$72M	-$42M	-69.9%
Net Income	-$63M	-$40M	-57.9%

Revenue Segments

Co Promote Agreement

$10M63%

Collaborative Arrangement Revenue

$5M37%